Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Zimmer Partners LP

Zimmer Partners LP lessened its position in Disc Medicine, Inc. (NASDAQ:IRON) by 3.8% in the 4th quarter, Holdings Channel reports. The fund owned 33,100 shares of the company’s stock after selling 1,300 shares during the period. Zimmer Partners LP’s holdings in Disc Medicine were worth $2,099,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sterling Capital Management LLC lifted its holdings in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Disc Medicine in the 4th quarter valued at about $235,000. Fiduciary Trust Co acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $257,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $285,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the topic of several recent analyst reports. BMO Capital Markets increased their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, May 12th. Wedbush reiterated an “outperform” rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $98.80.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $50.08 on Wednesday. The firm’s 50 day moving average price is $45.97 and its 200 day moving average price is $55.00. The firm has a market cap of $1.73 billion, a P/E ratio of -12.58 and a beta of 0.77. Disc Medicine, Inc. has a 1 year low of $30.65 and a 1 year high of $68.73.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.03). As a group, equities analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In related news, Director Mona Ashiya sold 10,011 shares of Disc Medicine stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.00, for a total value of $540,594.00. Following the transaction, the director now owns 187,297 shares in the company, valued at approximately $10,114,038. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Jacob Savage sold 2,100 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total value of $105,357.00. Following the sale, the insider now directly owns 66,398 shares of the company’s stock, valued at approximately $3,331,187.66. This trade represents a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold 342,833 shares of company stock worth $18,602,418 in the last 90 days. 4.24% of the stock is owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.